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tables. The vast majority of included studies were carried out in Europe, being 4 of 
them in United Kingdom. Ten studies considered lifetime horizon and two studies 
five- and one-year horizon. Diabetics and non-diabetics patients were taken into 
account in almost all models. Changes in body mass index (BMI) promoted by the 
pharmacotherapy were correlated to the risk of experiencing coronary heart dis-
eases, stroke or death in ten studies. Furthermore, two models took into account 
natural BMI increasing due to population ages. Besides BMI, some models were 
sensitive to changes in total cholesterol, HDL, systolic blood pressure and gly-
cated hemoglobin for diabetics. Finally, equations derived from Framingham Heart 
Study (FHS) were the most common ones used to populate models and competing 
risks events were not discussed in most of studies. ConClusions: Health-state 
transition modelling seems to be the most appropriate methodology to assess 
obesity’s pharmacotherapy. Future studies should explore other co-morbidities 
and competing risks events. Furthermore, equations used to populate models 
must be coherent to target population characteristics.
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objeCtives: Rare diseases (RD) are an important bench test case for healthcare 
services organization. This for both moral and ethical aspects which implies know-
ing how to cope with the needs of a vulnerable sector of population. At the same 
time RD its a challenge for healthcare service organizations, which are called to 
respond to particularly emphatic individual requirements. Methods: The study 
has been developed on administrative database of the Regional health care system 
of Lombardia Region, containing all the services provided to resident population 
and the related costs (or tariffs recognized by the the Regional System). The analy-
sis includes all the citizen benefiting of an exemption from copayments due to 
a rare diseases condition. The RHS (regional health care system) perspective has 
been adopted. Results: The analysis covered 44,548 subjects with copayment 
exemption due to RD. The prevalence (2012) was equal to 0.46% of the resident 
population, with a significant gender difference: 0.39% for males and 0.53 % for 
females. The average annual expenditure per rare diseased patient amounts to € 
5,003.1, a value approximately comparable to the average one for patients with at 
least two chronic conditions (€ 4,500.2). In terms of gender the figure for women 
(€ 3,539.3) is significantly lower than that for males (€ 6,856.6). The total impact 
on RHS is € 222.9 M, equal to 1.21% of regional spending. Patients with ultra rare 
disease are characterized by costs (€ 6,953.6 pro capita) significantly above the aver-
age. ConClusions: the research give some original insight on the prevalence and 
economic impact of RD patients in a large population. It permits to appreciate the 
potential organizational and economic impact od RD patients, especially of those 
with an ultra-rare condition, as well as financial risk for the local health care units 
due to prevalence concentration.
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objeCtives: In Germany, orphan drugs are assessed based on their EMA orphan 
designation and expected annual budget impact. Per German law, the additional 
benefit criteria is automatically met if the product is a qualified orphan drug. 
Products with expected annual budget impact of ≤ € 50 million annually qual-
ify and therefore are only required to submit an abbreviated dossier. Products 
with expected budget impact > € 50 million must submit a full dossier and are 
assessed on ability to demonstrate added benefit. This examines how orphan 
drugs have been reviewed post-AMNOG in Germany, including their resulting price 
rebates. Methods: GfK reviewed all EMA orphan-designated market authoriza-
tions since 2011 and cross-referenced products with the dossier submitted. GfK 
then reviewed G-BA resolutions to determine which target populations, population 
sizes, and comparators had been evaluated to determine final benefit assess-
ments. Subsequently, individual product prices were researched to determine the 
corresponding negotiated AMNOG rebates. Results: From 2011 to 2015 40 EMA 
orphan designated products received marketing authorization - only 16 of these 
products were assessed as orphan drugs in Germany. Of these, 10 were indicated 
for oncology (62.5%) and 6 (37.5%) for non-oncology indications. In their largest 
sub-populations, 8 (50%) products achieved ‘minor additional benefit’, 6 (37.5%) 
received ‘unquantifiable additional benefit,’ while only 2 (12.5%) achieved ‘con-
siderable additional benefit.’ Across 11 products, the average total rebate (AMNOG 
negotiated rebate + mandatory rebate) was 32%, however, varied highly and ranged 
between 15% and 50%. Our analysis also looked across other factors (e.g., rebate as 
it relates to benefit rating). ConClusions: Due to their expected budget impact, 
most EMA orphan-designated drugs did not qualify for the abbreviated dossier. 
However, neither a full or abbreviated submission could concretely be linked to 
a higher benefit assignment; high benefit scores do not necessarily guarantee 
smaller rebates off the free price.
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objeCtives: Informal caregiver burden is not formally or routinely considered in 
health technology assessment (HTAs). However, the burden of many diseases on 
informal caregivers’ quality of life has been recognized, including hematologi-
cal cancers. This study aimed to understand the role of informal caregiver burden 
in HTA in France, Germany, and the US, using the example of multiple myeloma 
Furthermore, the highest approved ICER value of all NICE appraised rare disease 
submissions was noted at £47,200/QALY, while 7 technologies with ICERs above 
£50,000/QALY were rejected. ConClusions: ICER thresholds in the UK continue 
to be barriers to access therapies for rare diseases, although recent policy revisions 
may lead to changes in access in this market.
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objeCtives: Assessing the economic value (EV) of orphan drugs (ODs) within the 
existing health technology assessment (HTA) framework is challenging. We therefore 
decided to evaluate current and alternative HTA approaches for ODs. Methods: 
Published studies from 2000 to July 2014 focusing on methods for assessing the 
EV of ODs were identified via MEDLINE. A targeted search for recent HTA submis-
sions was also performed, covering five ODs we selected as most relevant (bosu-
tinib, brentuximab vedotin, everolimus, pomalidomide and ruxolitinib) across six 
European countries (France, Germany, Ireland, the Netherlands, Sweden and the 
UK). Results: Eleven published papers were identified. All papers concluded that 
ODs are not suited to standard economic evaluations and the current HTA frame-
work. The primary reasons were inadequate evidence of efficacy due to low patient 
numbers, lack of important outcome measures such as quality of life, no long-term 
outcomes data, and no information on the systemic impact of the disease beyond 
the health impact, i.e. financial, emotional and social. The inherent uncertainty 
regarding short- and long-term health gains combined with high acquisition costs 
leads to incremental cost-effectiveness ratios well beyond existing HTA thresh-
olds. We identified alternative methods such as including societal value, emphasis-
ing burden of illness and using variable thresholds, weighted outcome measures, 
surrogate markers and alternative statistical approaches like Bayesian methods. 
However, none of these have been implemented in existing HTAs. We confirmed 
this in our review of HTAs, which also showed inconsistency in decisions taken by 
HTA bodies. ConClusions: Assessing EV of ODs remains a challenge. Despite being 
discussed in the literature, no innovative methods have been used in recent HTA 
submissions. HTA bodies, companies developing ODs, patients and society must 
engage in further discussions on how to assess value. Until then, considerable risk 
remains that access to ODs is unequal compared to non-ODs and across countries.
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objeCtives: To understand European Union (EU) and Australian payer perceptions 
and challenges in the evaluation of emerging health technologies with orphan and 
ultra-orphan designations. Methods: In-depth, qualitative, one-on-one inter-
views were conducted with payer decision makers representing Australia and the 
EU-5: France, Germany, Italy, Spain, and the United Kingdom from the RTI Health 
Solutions Payer Advisory Panel. Results: Payers identify the biggest challenges as 
lack of clinical and comparative efficacy data and pressures from advocacy groups, 
patients, and prescribers to fund the ever-increasing numbers of orphan and ultra-
orphan technologies, which are often very expensive and have limited clinical evi-
dence. Understanding the disease and its burden and unmet needs was consistently 
highlighted. All payers estimated that spending for orphan and ultra-orphan tech-
nologies will increase significantly in the next 5 years, leading to concerns over 
future funding and budgets. Clawbacks in France will be common; employment 
of the rule of rescue in Australia and pricing pressures in Italy, Spain, and the UK 
are to be expected. Payers wanted to see better-defined patient populations and 
unmet needs accompanied by well-defined treatment courses (e.g., when to stop 
treatment). Benefits of new technologies will not be captured in traditional health 
economic analyses, thus increasing uncertainty. Bridging the clinical evidence with 
other robust data will be critical. The cost to the systems was highlighted as a con-
sistent concern. More emphasis on showing the value, affordability, comparative 
effectiveness, and cost offsets is critical. ConClusions: Payers are seeking more 
value-based information to better inform decision making in the evaluation of new 
orphan and ultra-orphan technologies. The challenge lies with the value of the new 
technology and who is judging that value. Rising costs of orphan and ultra-orphan 
technologies will have more impact on market access in the future, with increasing 
resistance to high prices.
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objeCtives: To describe and discuss existing pharmacoeconomic models assess-
ing obese or overweight patients being treated with anti-obesity drugs Methods: 
Medline and EMBASE were searched for cost-effectiveness or cost-utility-analy-
sis reporting in full decision modelling used. It was eligible for assessment only 
studies considering Quality Adjusted-Life Years or Life-Year Gained as the final 
outcome and assessing pharmacotherapy as intervention. Data regarding popula-
tion, study’s perspective, time-horizon and methodology used were described. It 
was discussed the sensitivity of the model for obesity’s co-morbidities such as 
cardiovacular diseases and type 2 diabetes mellitus and their reliability with clini-
cal practice. In addition, it was explored the risk equations used to populate the 
model. Results: From 51 studies assessed in full, twelve of them complied with 
our inclusion criteria being that were identified twelve different models. The most 
common methodology used was health-state transition modelling followed by life-
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erate hemophilia (p= 0.01), HIV (p< 0.01), HCV (p= 0.02), and factor usage (p= 0.02) 
were significantly associated with ABF. Fewer variables had a significant associa-
tion with ABF for children compared to adults, including prophylaxis (p< 0.01) and 
factor usage (p= 0.01). ConClusions: Variables associated with ABF include socio-
demographics, clinical characteristics and factor usage. The preliminary results 
reinforce the importance of optimizing treatment for individual differences. Future 
studies should investigate how variations in bleeding outcomes and treatment are 
associated with healthcare costs.
rESEArcH PoStEr PrESEntAtionS – SESSion v
rESEArcH on mEtHodS StUdiES
rESEArcH on mEtHodS – clinical outcomes methods
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objeCtives: A key objective of treating type 2 diabetes mellitus (TD2M) is main-
taining glycaemic control, (glycated haemoglobin-HbA1c) with targets set between 
6.5%-7.5%. Doctors frequently fail to intensify treatment in uncontrolled patients 
and a study was designed to assess the long term clinical effects of this inertia. The 
study involved Classification and Regression Tree (CART) analyses to evaluate the 
timepoint that intensification should occur to gain glycaemic control. Methods: 
Incident T2DM patients were identified in the UK CPRD database between 1 January 
2000-31 August 2014 and followed for 5 years. Patients initiated on metformin 
monotherapy and did not achieved HbA1c< 7% after 90 days. CART was applied, 
with Hba1c level as the dependent variable and three explanatory effects: time to 
intensification class (TTIc), Year and Year by TTIc interaction. For each iteration TTIc 
was assigned per subject (i.e. those patients with TTI before or after TTI cut-point). 
The goodness of fit, the Akaike Information Criteria (AIC), was obtained for the 
model and the optimal cut point was the one resulting in the lowest AIC value. This 
created two classes of subjects, rapid and delayed TTI, whose HbA1c values were 
compared Results: The model identified that the optimal intensification time 
was ≤ 244 days post the first HbA1c≥ 7% (rapid TTI). 50.7% of patients with rapid TTI 
achieved HbA1c target< 7%, compared to only 14.0% in delayed TTI, despite rapid 
patients starting with higher average HbA1c levels (8.65%) than delayed patients 
(7.85%). The effects of rapid intensification caused immediate and maintained 
reduction in glucose levels, not observed in the delayed group. ConClusions: 
CART analysis identified the optimal timing for treatment intensification post loss 
of glycaemic control as ≤ 244 days. This analytical method could be used in future 
database studies to aid in group definition by treatment exposure and provide valu-
able clinical information for physicians.
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objeCtives: Use of surrogate endpoints like progression-free survival (PFS) and 
time to progression (TTP) instead of overall survival (OS) in clinical trials for 
advanced cancer remains challenging from a health economic standpoint. This 
study assessed the use of surrogate endpoints in economic evaluations of anticancer 
drugs and methodological approaches adopted when reliable OS data are unavail-
able. Methods: A systematic literature review was conducted to identify economic 
evaluations of treatments for advanced cancer published between January 2003 
and October 2013. Cost-effectiveness and cost-utility analyses expressed in terms 
of cost per life-year gained and cost per quality-adjusted life-year using a surrogate 
endpoint as an outcome measure were eligible. Characteristics of selected stud-
ies were extracted and comprised: population, treatment of interest, comparator, 
line-of-treatment, study perspective, and time horizon. Use of surrogate endpoints 
and methods adopted when OS data were lacking were analyzed. Two reviewers 
independently selected studies and extracted data. Results: In total, 7,219 stud-
ies were identified and 100 fulfilled the eligibility criteria. Most included studies 
assessed the cost-effectiveness of a biological therapy (65%) in the first-line setting 
(56%) and in the context of advanced non-small cell lung cancer (24%) or advanced 
breast cancer (22%). Surrogate endpoints mostly used were PFS and TTP, account-
ing for 92% of included studies. OS data were unavailable for analysis in nearly 
25% of economic evaluations. In the absence of OS data, studies most commonly 
assumed an equal risk of death for all treatment groups. Other methods included 
use of indirect comparison based on numerous assumptions, use of a surrogate 
endpoint as a proxy for OS, consultation with clinical experts, and use of OS data 
associated with different patient populations or treatment-line. ConClusions: 
Although several approaches are used, there is no consensus method to estimate 
the cost-effectiveness of new anticancer drugs in the absence of reliable OS data.
Prm3
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of contrASt mEdiA in inPAtiEnt intErvEntionAl cArdiovAScUlAr 
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David G1, Johnson M2, Lim L3, Mallow PJ4
(MM). Methods: Telephone interviews lasting approximately 1 hour were conducted 
with two HTA experts from each country, based on an interview guide. Interviews were 
recorded and common themes identified from assessment of the narrative. Results: 
The French advisors considered that the cost savings realized through informal care 
compared with formal caregiving are neglected, and that data on informal caregiver 
burden should be incorporated into cost-effectiveness models where available. The 
German advisors suggested that caregiver burden may be recognized in HTA if it can 
be related to patient benefit. Discussions in this area are increasing but changes to 
the acceptability of caregiver burden data was mostly likely to occur elsewhere in the 
healthcare system (i.e., outside of the benefit assessment process). Advisors in the US 
reported that payers’ views of caregiver burden are changing and that this information 
should be considered as more patients involve their caregivers in decision-making, or 
caregivers make the decisions (for some groups of patients). ConClusions: Informal 
caregiver burden data are not currently considered important in HTA in Europe or 
the US, although there are suggestions that this may change. Even where such data 
have been included in HTA submissions, they have not generally been a driver of 
HTA decision-making.
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objeCtives: Data from real-world European settings describing treatment patterns 
and outcomes in relapsed/refractory multiple myeloma (RRMM) are limited. This 
study helps address this knowledge gap using a brief physician survey. Methods: 
Sixty-one physicians treating RRMM were surveyed (November 2014) in France 
(n= 21), Germany (n= 20), and the United Kingdom (UK) (n= 20). The survey collected 
physicians’ opinions on typical treatment patterns and outcomes of RRMM patients 
in the relapse/refractory setting (following disease progression during/after first-
line therapy). Analyses were descriptive. Results: Sixty percent of physicians in 
France and the UK were haematologists, versus 10% in Germany (where 80% were 
onco-haematologists). The proportion of patients with high-risk disease based on 
ISS stage and cytogenetics was 18%-24% across countries. Bortezomib/thalidomide/
dexamethasone was the most common induction regimen (42%) for stem cell trans-
plant (SCT)-eligible patients in France, but was unused in Germany and less com-
monly prescribed in the UK (17%); bortezomib/cyclophosphamide/dexamethasone 
was the reported induction therapy for 28% of SCT-eligible patients in all coun-
tries. Regardless of SCT status, lenalidomide/dexamethasone was the predominant 
second-line treatment (37%-48%) reported in France and Germany; in the UK, 
second-/later-line regimens were more varied, with both lenalidomide- and bort-
ezomib-based regimens being reported as common. Second-/later-line therapy dura-
tion was generally short, particularly in the UK where 75% of physicians reported 
a < 6-month duration. Disease progression was the top reason for second/later-
line discontinuation; other common reasons included toxicity and completion of 
planned therapy course. For high-risk patients, > 75% of physicians reported median 
survival of < 1 year from first relapse. ConClusions: The proportion of RRMM 
patients with high-risk disease in real-world settings (18%-24%) may exceed that 
reported in clinical trials (10%-15%). Second-/later-line therapy duration is typically 
short (< 6 months). Survival prospects for RRMM patients remain limited, particu-
larly for high-risk patients. Patient-level studies are needed to better characterize 
the unmet needs in RRMM signaled by our findings.
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objeCtives: Bleeding episodes pose significant economic and quality-of-life (QoL) 
burdens on persons with hemophilia. This study aims to identify socio-demo-
graphic and clinical characteristics associated with annual bleeding frequency 
(ABF). Methods: Between 2005-2007 and 2009-2012, the Hemophilia Utilization 
Group Studies Va and Vb, respectively, recruited hemophilia A or B patients from 
ten geographically diverse Hemophilia Treatment Centers in the United States. 
Adult patients or parents of children completed a baseline survey that collected 
information regarding socio-demographics, clinical characteristics, and treatment 
patterns. During the two-year observation period, bleeding episodes were collected 
through regular patient follow-ups. ABF was calculated as the annualized sum of 
patient-reported bleeding episodes. Two-year drug dispensing information was also 
recorded and annualized. Multivariable linear regressions were used to assess the 
association of patient variables with ABF. Results: Of 477 recruited patients, 317 
with complete baseline and utilization data and at least three months of patient 
follow-up were included. Among included patients, 49.8% were children, 39.7% used 
prophylaxis, and 63.1% had severe hemophilia. Variables significantly associated 
with ABF included 37 or older vs. 2-9 years of age (p= 0.03), married or with a partner 
(p= 0.03), hemophilia B (p= 0.09), mild/moderate hemophilia (p= 0.01), prophylaxis 
(p< 0.01), human immunodeficiency virus (HIV) (p< 0.01), hepatitis C virus (HCV) 
(p< 0.01), and annual factor usage per kilogram of body weight (p< 0.01). Among 
adults, age in years (p= 0.07), no insurance vs. public insurance (p= 0.04), mild/mod-
